• EyePoint’s third-quarter 2026 net loss widened 60% to $95.6 million, while total net revenue fell 20% to $800,000.
• Operating expenses jumped 55% to $97.6 million, primarily due to ongoing DURAVYU Phase 3 trials for wet AMD and DME.
• A planned 53% workforce reduction and operational adjustments are expected to generate approximately $30 million in annualized savings.
• Resources will prioritize DURAVYU’s fully enrolled Phase 3 DME trials, with topline data expected early in the fourth quarter of 2027.
• Cash, cash equivalents and marketable securities totaled $118 million at September 30, 2026; projected funding extends into late third-quarter 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-456889), on November 12, 2026, and is solely responsible for the information contained therein.